A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

January 6, 2027

Study Completion Date

January 6, 2027

Conditions

Advanced Solid TumorMetastatic Solid Tumor

Interventions

DRUG

89Zr˗DFO˗REGN5054

Administered by intravenous (IV) infusion during Part A and B.

DRUG

cemiplimab

Administered by IV infusion every 3 weeks (Q3W).

Trial Locations (1)

RECRUITING

UMC Groningen, Groningen

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY